

Xgeva[®] (denosumab) Injectable Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

 Aetna Precertification Notification

 Phone:
 1-866-752-7021

 FAX:
 1-888-267-3277

For Medicare Advantage Part B: Please Use Medicare Request Form

Please indicate: Start of tre	eatmen	t: Start date:			Continuation of therap	y: Date of la	ast treatme	nt <u>/</u>	/
Precertification Requested By:					Phone:		Fax:		
A. PATIENT INFORMATION									
First Name:			Last Name:				DOB:		
Address:			City:				State:	ZIP:	
Home Phone:	,	Work Phone:		Ce	ell Phone:		Email:		
Current Weight: lbs	or	kgs	Height:	inch	nes orcm	s Allergies:			
B. INSURANCE INFORMATIO	Ν								
Aetna Member ID #:			Does patient have	other of	coverage? 🗌 Yes 🗌 I	No			
Group #:			If yes, provide ID#: Carrier Name:						
Insured:			Insured:						
Medicare: Yes No If yes,	provide	• ID #:	-	Medi	i caid: 🗌 Yes 🗌 No If	yes, provide	ID #:		
C. PRESCRIBER INFORMATIO	DN								
First Name:			Last Name:	Last Name: (Check or				D.O. N.P.	□ P.A.
Address:			City:				State:	ZIP:	
Phone:	Fax:		St Lic #:		NPI #:	DEA #:		UPIN:	
Provider Email:			Office Contact Nar	ne:			Phone:		
Specialty (Check one): 🔲 Once	ologist	🗌 Hematologi	ist 🔲 Internal Medi	cine	🗌 Primary Care 🔲 G	/N 🗌 Othe	r:		
D. DISPENSING PROVIDER/A	DMINIS	TRATION INFO	ORMATION						
Place of Administration:					Dispensing Provider/	Pharmacy: (Patient sele	cted choice)	
Self-administered Physician's Office							Retail Pharmacy		
							-		
Center Name:					Name:				
Home Infusion Center	Pł	none:			Address:				
Agency Name:					Phone:				
Administration code(s) (CPT):					TIN:				
					·····				
E. PRODUCT INFORMATION		_			_				
Request is for Xgeva (denos	-				Frequency:				
F. DIAGNOSIS INFORMATION									
Primary ICD Code:									
G. CLINICAL INFORMATION - For Initiation Requests (clinica					i in its <u>entirety</u> for all pr	ecertification	i requests.		
Giant cell tumor of the bor		mentation requ	ulled for all reques	<u>(S):</u>					
		oc from thuroid	dearainama						
Palliative care for bone me Prevention of skeletal-rela				ono m	notastasos from solid	tumore			
U Hypercalcemia of malignation						tuniors			
\rightarrow \square Yes \square No Is the pat	-	ondition refracto	orv to IV hisphospho	nate (e	e a zoledronic acid na	midronate) t	herany?		
					nt with an IV bisphosph			impairment, rer	าลไ
		insufficiency [ci	reatinine clearance l	ess tha	an 35 mL/min], history o	of intolerance	e to an IV bi	sphosphonate)	?
🖵 Treatment for osteopenia o									
\longrightarrow \Box Yes \Box No Is the path								-line therapy?	
\longrightarrow \Box Yes] No	Is the patient u	nable to take a bisph	nospho	onate because of renal i	nsufficiency	?		
For Continuation Beguaste (a)	inical -	locumentation	roquired for all rea		.).				
For Continuation Requests (cl						ancad by di	saasa atabil	ity or	
Yes No Is the patient ex disease improv			om therapy with the	reques	sted medication as evid	enced by dis	sease stabil		



Xgeva[®] (denosumab) Injectable Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

 Aetna Precertification Notification

 Phone:
 1-866-752-7021

 FAX:
 1-888-267-3277

For Medicare Advantage Part B: Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB			
H. ACKNOWLEDGEMENT						
Request Completed By (Signati	Date: / /					

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.